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a b s t r a c t
The recommended radio-therapeutic treatment for cervix cancer consists of a first phase of
external beam radiotherapy (EBRT) plus a second phase of brachytherapy (BT), the combined
treatment being delivered within 8 weeks.
In order to assess a comprehensive dosimetry of the whole treatment, it is necessary to
take into account that these two phases are characterized by different spatial and temporal
dosimetric distributions, which complicates the task of the summation of the two contribu-
tions, EBRT and BT. Radiobiology allows to tackle this issue pragmatically by means of the
LQ model and, in fact, this is the usual tool currently in use for this matter.
In this work, we describe the rationale behind the summation of the dosimetric contribu-
tions of the two phases of the treatment, EBRT and BT, for cervix cancer, as carried out with
the LQ model.
Besides, we address, from a radiobiological point of view, several important considerations
regarding the use of the LQ model for this task. One of them is the analysis of the effect of
the overall treatment time in the result of the global treatment. Another important question
considered is related to the fact that the capacity of LQ to predict the treatment outcomes is
deteriorated when the dose per fraction of the radiotherapic scheme exceeds 6–10 Gy, which
is a typical brachytherapy fractionation. Finally, we analyze the influence of the uncertainty
and the variability of the main parameters utilized in the LQ model formulation in the
assessment of the global dosimetry.
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1. Background
Nowadays, the recommended radiotherapeutic treatment to
ensure loco regional control and survival of patients with cer-
vical cancer consists of the combination of external beam
radiotherapy (EBRT) and a brachytherapy boost (BT).1–5 Several
studies suggest that a contribution of 50% of either technique
to the equivalent dose in 2 Gy per fraction (EQD2) of the global
treatment leads to an optimal therapeutic window, reaching to
a D90 for the high risk CTV (CTVHR) of 85–90 Gy EQD2.1,6–9 The
most relevant organs at risk (OR) are the bladder, whose dose
constraint is 90 Gy EQD2, the rectum and sigmoid, whose dose
constraints are 75 Gy EQD2, the bowel and the vagina.1 These
constraints are referred to the most exposed 2.0 cc (D2cc) of
the mentioned OR.
Currently, there are several schedules in use combining
both techniques. The EBRT is usually delivered in 25 fractions
of 1.8–2 Gy, separated by enough time to allow normal tissue
recovery, typically one day, in such a way that the treatment
spans five weeks. On the other hand, the BT may deliver the
dose by means of different temporal patterns: a continuous
low dose rate regime (LDR) (0.5 Gy h−1), pulsed rate (PDR) for
several days (0.5–1 Gy h−1), or high dose rate (HDR) (>12 Gy h−1)
by delivering several fractions in several days or weeks.1,10,11
Nevertheless, the actual trend reveals preference for the HDR
scheme given its advantages over the other techniques.12 For
instance, high dose rate brachyterapy (HDR-BT) is more con-
venient for the patient, easier to administrate and it allows
dose optimization to normal tissues. In addition, it represents
an economic benefit for the center in comparison to other
BT techniques. For this reason, from this point forward we
will consider only the treatment composed by an EBRT and
HDR-BT phases.
The schedule proposed by the University of Viena8 is widely
accepted and commonly used. It consists of an EBRT phase of
45–50 Gy followed by two applications of HDR-BT separated by
about one week, with two fractions each (7 Gy nominal per
fraction). Other treatment schedules are also put into prac-
tice, the main difference between them being the temporal
distribution in which the dose fractions of BT are delivered.
In any case, the total treatment (EBRT + BT) should not be
longer than 8 weeks to achieve better tumor local control and
survival.9,12–14
The biological effect caused by the dose absorption
depends on factors such as the treated volume, the dose and
dose rate distributions, the dose per fraction or pulse, the time
interval between fractions or pulses, the overall treatment
time, the radiation quality (LET), other therapeutic interven-
tions (hyperthermia, chemotherapy, etc.), factors related to
the patient (comorbidity) and factors related to the tumor
(hypoxia).1,11,15 The dose per fraction, the dose rate and the
treatment time are important concepts that differ in both
techniques, EBRT and BT, regarding the temporal distribution.
Another relevant difference between the EBRT and the
BT, which is an important factor in the effect of the radia-
tion, is the different level of homogeneity of the distributions
generated. The EBRT aim is to deliver dose as homoge-
neous as possible in the volume of interest, with variations
between 95% and 107%.11,16–18 On the other hand, the BT is
characterized by high heterogeneous dose distributions even
in small target volumes, due to the rapid and continuous
dose fall close to the radioactive sources according to the
inverse square distance law and the effective absorption
of the dose by the tissues.15 The whole CTV comprehends
a minimum dose, and on the inside it receives in great
part of the volume a higher dose and dose rate in the
vicinity of the radioactive sources.15 On average, the gross
tumor volume (GTV) may receive up to 150% of the dose
arriving at the CTV periphery, from which a steep drop of
dose and dose rate is produced.1 Actually, this high hetero-
geneity produces an important increment in the biological
effect.19
Such differences in the spatial and temporal dosimetric
distributions of the EBRT and the BT make the addition of its
dosimetric contributions to the total dose distribution a very
complex process. Furthermore, even though the register of the
image studies of the EBRT and BT phases may be considered
as a tool to perform this sum, the variations of the anatomy of
the patient during the whole treatment jeopardize this solu-
tion, making this task even more complicated. Understanding
all the aforementioned differences, radiobiology provides us
with proper tools to know how to add the contribution of each
treatment phase.
The commonly accepted practice to compute the cumula-
tive sum of the doses delivered by the EBRT and the BT1,20
implies the assumption of several approximations which
make this task easier: the volumes or point of interest in the
BT phase are considered to be irradiated uniformly by the pre-
scription dose of the EBRT. This assumes that there is no area
in the OR which is irradiated by a dose lower than that pre-
scribed in the EBRT phase, which represents a conservative
scenario for the OR, and is also more reasonable for the target,
since the CTVHR defined in the BT is a sub-volume of the PTV
defined in the EBRT. Therefore, the summation of the contribu-
tions of the two phases of the treatment is based on the mere
addition of the doses of the BT phase in the points and vol-
umes of interests plus the prescribed dose in the EBRT phase,
being both previously converted to their equivalent in 2 Gy per
fraction, a process usually known as parametric sum.21,22 This
strategy facilitates the use of the linear quadratic model (LQ)
to perform the assessment of the dosimetric distributions of
the EBRT and the BT.23
It is convenient to take into account that the basic formu-
lation of the LQ model does not consider the effect of the
overall treatment time. This model should be corrected in case
a comparison were to be made between the different treat-
ment schedules with their corresponding overall treatment
times. More importantly, the model should be corrected before
assessing the efficacy of the cervical cancer treatment.24 This
is one of the questions we are going to analyze in this work
from a radiobiological point of view: the influence of the over-
all treatment time in which the EBRT and the BT are delivered
in the result of the global treatment.
Another important feature to be considered is that the LQ
model may overestimate the biological effect if the dose per
fraction surpasses 6–10 Gy.25,26 Below this range, we will get
proper estimations by assuming a complete repair of the sub-
lethal damage between fractions and protocols with similar
repopulation processes and cellular redistribution.1 In this
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work, we will also study the LQ model in this context, and
its application will be analyzed.
Finally, we will also address the effect of the uncertainty
and the variability in the parameters used in the LQ model.
2. Theoretical framework: the LQ model
The LQ model is the recommended one for the comparison
and evaluation of treatments with different fractionations and
dose rates.11,15,27–29 In this model, the cell survival fraction, S,
in the presence of radiation exposure, decreases as the deliv-
ered dose, d, increases according to the following equation:
S = exp(−˛d − ˇd2) (1)
The parameters ˛ and ˇ specify the sensitivity of the cell to
the radiation.
Assuming that each successive fraction of the treatment
produces equivalent effects, a biological effect predictor of the
radiation is defined within the LQ model context as a function
of the dose per fraction, d, the number of fractions, n, and the
parameters ˛ and ˇ:
E = − ln (S)n = n(˛d + ˇd2) (2)
This equation is applicable to treatment schedules for
which total recovery of normal tissue is assumed, such as
EBRT and HDR. There is no need for corrections related to the
different dose rates of these techniques, since the biological
effects produced by them are similar, except for dose differ-
ences resulting from the different dosimetric homogeneities.1
On the contrary, for LDR and PDR regimes it is necessary to
take into account that the repair of sub-lethal damage starts
after 15–30 min, this fact is the most influential factor for
the radiation effect.11 It is assumed that the repair kinetics
is determined by a recovery mean time, T1/2 (time for half of
the DNA damage to be repaired). Therefore, the LQ model is
modified as follows:
ELDR,PDR = (˛D + gˇD2) (3)
where D is the total absorbed dose. The g factor, known as Lea-










where  = ln 2/T1/2 is the recovery rate constant and t is the
total time.
For PDR, an incomplete repair is assumed between and dur-
ing fractions, in which the dose is delivered as an accelerated










Y = 1 − e−t
P =
[
NK − K − NK2e−t + KN+1e−Nt
(1 − Ke−t)2
]
with K = exp (−t).
In this case t is the length of time of each pulse, x is the
time between pulses and N is the total number of pulses.
It is usual to consider T1/2 = 0.5–1 h for early-responding tis-
sues and tumors, and T1/2 = 1.5 h for late-responding tissues.11
The figure that quantifies the biological effect of the radi-










Mathematically, it is defined as the dose required to yield
the effect E produced by n fractions of d Gy in an infinite num-
ber of fractions of infinitely small doses. ˛/ˇ quantifies the
tissue sensitivity to fractionation changes. Early-responding
tissues, of high ˛/ˇ (7–20 Gy), are not as sensitive to fraction-
ation changes as late-responding tissues, characterized by
lower ˛/ˇ (0.5–6 Gy). When two treatments lead to the same
tissue effect, E and ˛ are constant, and therefore its BED can
be equalized in order to compare both treatments.
As previously mentioned, the biological effect of the radia-
tion depends, among other factors, on the temporal schedule
in which the dose is delivered, that is, its dose per fraction
and dose rate. Therefore, in order to know the total biologi-
cal or clinical effect of the combination of EBRT and BT, both
treatment schedules should be translated into a common
treatment schedule. The great clinical experience gathered
throughout the history of radiotherapeutic treatments deliv-
ered at 2 Gy per fraction makes this schedule the appropriate
one to perform comparisons and additions between treat-
ments with different conditions, and consequently it is usual
to take it as the reference radiotherapeutic schedule.1 Hence,
the equivalent dose to 2 Gy per fraction, EQD2, is defined as the
dose to be delivered with 2 Gy per fraction to obtain the same
biological effect as the treatment under consideration obtains.
Accordingly, if two treatment schedules with the same LET and
similar dose rates, a generic one with total dose D = nd and a
reference one, have the same effect, Eq. (6) can be equalized


















3. Addition of EBRT AND BT
As previously mentioned, if we consider that during the EBRT
the volumes of interest (D98, D90, D50 regarding the CTVHR
and D0.1cc, D1cc y D2cc for the OR1,32 and points of interest
(A points) are irradiated uniformly by the prescription dose,
the LQ model provides a formulation with which it is pos-
sible to easily perform the summation of the doses of both
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treatment phases, EBRT and HDR-BT. The total BED will be the
summation of the BED of each of those phases:
BED = BEDEBRT + BEDHDR−BT (9)
The absorbed doses by the points or volumes of inter-
est of the target and OR of both techniques will be used
to compute the EQD2 of each of them, in this way simu-
lating treatment phases with identical fractionation and
dose rate, making it possible to add these figures in order
to obtain the EQD2 of the whole treatment.22 This simple
approach is easy to perform in practice, and in fact, it is the
scenario recommended to perform the summation of the
cumulative dose of both treatments for cervix cancer.1,15,32
It is a conservative scenario which tends to over-estimate
the dose to the normal tissue, foreseeing the existence of
toxicity, but giving a reasonable estimation for the doses
to the OR.21 Regarding this, worksheets have been supplied
for the radiobiological assessment in the clinical practice
(http://icru.org/content/reports/prescribing-recording-and-reporting-brachytherapy-for-cancer-of-the-cervix-report-no-89).
However, the most conservative scenario guaranteed by
this approximation, although reasonable,20,21,33 is not what
is really happening. The dosimetric distributions are not per-
fectly homogeneous and, in fact, in order to describe the shape
of a dose-volume histogram (DVH) several values of dose-
volume, DV, are needed, selected in such a way that they
can be correlated with the final effect.1 Specifically regarding
techniques such as IMRT or VMAT, in which high conformed
dosimetric distributions are intended, but not necessarily uni-
form in the OR,33 in general it would not be true that the
sub-volumes of the walls of the OR close to the CTVHR were
irradiated the same as the more distant sub-volumes.1,32,34
It will also be necessary to consider whether a boost in the
parametrial region or a nodal boost is performed as part of
the EBRT treatment, since it will contribute additionally to the
dose delivered to the volumes of interest at the moment of
the HDR-BT.35–38 In such cases, a more realistic assessment of
the relevant dosimetric parameters could allow a dose esca-
lation for the target volumes.21 The heterogeneity of the total
dose distribution of the combination of EBRT and HDR-BT will
depend, to a large extent, on the weight of the contributions of
each technique to the global treatment, so that the more the
HDR-BT is weighted, the more heterogeneous the distribution
will be.1
In the context of image guided brachytherapy for cervix
cancer, the gold standard implies at least one image study
per application.1 The summation of the contributions of the
EBRT and the HDR-BT will consider the dosimetric distribu-
tions as static in the different image sets performed during
the treatment, typically a CT, where the EBRT dosimetry is per-
formed, and the image studies (MR or CT) carried out during
the BT phase. Therefore, the most irradiated sub-volume of
each OR is supposed to be the same throughout the HDR-BT
fractions.22,32 In reality, during the treatment the ORs move
and deform to a greater or lesser extent depending on the
organ in question.1 Also, the hot spots in the OR walls may
or may not be continuous.32,39 In addition, the applicator may
modify its position from application to application, changing
substantially the topography of the tissue.1,21,32 And finally,
the tumor changes its volume and configuration, which also
influences the OR configuration.32,40 Additionally, in implants
with interstitial component the irradiated target volumes with
low doses may be at different locations throughout the dif-
ferent BT fractions. Therefore, the static scenario which is
implicit in the approximation assumed when adding EBRT
and HDR-BT, would not always be the most representative
one, and thus, each particular clinical case should be con-
sidered carefully in order to analyze the suitability of the
approximation.1,22,33
The most suitable and broadly accepted tool to evaluate
the dose in the considered volumes and its homogeneity is
the DVH, which is usually evaluated in its cumulative form,
although its differential form provides relevant information
which would be important to take into account also (one
example of this is the use of the differential DVH to com-
pute the generalized equivalent uniform dose, gEUD, for OR).41
The precision of the histograms depends on the treatment
planning system (TPS) and the algorithm used in it, and may
influence the results of the analysis.15 Nevertheless, the DVH
lacks the informati n relat d to spatial distribution of the
dose in a specific volume, which is an intrinsic limitation of the
DVH. The fact of adding the dose of EBRT and HDR-BT without
taking into account how the spatial distribution of the dose
varies in the volumes may over-estimate the EQD2 in the OR,
jeopardizing the target coverage during the dose optimization
process.1,39 It is impossible to have a single DVH with totally
comprehensive information of both contributions.21,23,29 This
is the reason why, ideally, the summation of both radiother-
apy phases should take into account the radiation effect at a
cellular level.1
The methods based on a voxelized dosimetry do not take
into account the changes of the volumes produced through-
out the global treatment, thus being insufficient for a precise
assessment of the whole treatment effect.1 But up to now,
there has been no method to take into account the temporal
evolution of the dose distribution throughout the treatment.
Therefore, due to the inter-fraction, intra-fraction and inter-
application variations, it is not possible to perform a rigid
registration of the different image sets.1,33,42,43 It would be
necessary to identify each irradiated voxel in each HDR-BT
fraction and match it with the correspondent irradiated voxel
in each HDR-BT fraction.1,32 The deformable register is a tech-
nique that tries to trace this historical information of the
irradiated volumes of interest, mapping the voxels between
the different image sets.22,44 One of the challenges of the
deformable register is to tackle the fact of having an appli-
cator in place in one of the image sets to be registered.1,45 In
the case of EBRT treatments, with or without boost, it seems
to provide more realistic results when estimating the dose to
the OR than a simple parametric summation.21 Although cur-
rently this research field is rather active, this technique has
not yet been clinically validated in a reliable way.1,21,22
3.1. Example: application of the LQ model to assess
the dose in the combined treatment of EBRT and HDR-BT
in cervix cancer
A cervix cancer patient follows a radiotherapy treatment con-
sisting of 25 fractions of EBRT of 1.8 Gy each, 5 days a week,
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Table 1 – Illustrative example of the computation of the total dose delivered (in Gy) by the combination of EBRT and
HDR-BT phases for a typical scheme of cervix cancer radiotherapy treatment. It is indicated in bold the dosimetric
variables and values upon which the recommended dosimetric constraints are referred, that is, D90 for the CTVHR and
D2cc for the ORs.
BT, Fraction 1 BT, Fraction 2 BT, Fraction 3 BT, Fraction 4 EBRT Total
D EQD2 D EQD2 D EQD2 D EQD2 D EQD2 EQD2
CTVHR D98 5.75 7.55 5.93 7.87 6.24 8.44 6.02 8.04
45 44.24
76.14
D90 7.08 10.08 7.22 10.36 7.41 10.75 7.15 10.22 85.65
D50 10.39 17.65 10.41 17.71 10.78 18.67 10.13 16.99 115.26
Bladder D0.1cc 6.33 11.81 6.35 11.87 6.26 11.59 6.56 12.54
45 43.20
91.01
D1cc 5.94 10.62 5.97 10.71 5.67 9.83 6.09 11.07 85.43
D2cc 5.75 10.06 5.83 10.30 5.38 9.02 5.81 10.24 82.82
Rectum D0.1cc 5.03 8.08 5.05 8.13 5.81 10.24 4.79 7.46 77.11
D1cc 4.56 6.89 4.59 6.97 4.67 7.16 4.38 6.46 70.68
D2cc 4.34 6.37 4.38 6.46 4.20 6.05 4.04 5.69 67.77
Sigma D0.1cc 5.51 9.38 5.53 9.43 5.30 8.80 4.79 7.46 78.27
D1cc 4.77 7.41 4.80 7.49 4.29 6.25 3.93 5.45 69.80
D2cc 4.40 6.51 4.42 6.56 3.82 5.21 3.60 4.75 66.23
to achieve 45 Gy. This treatment is combined with 2 HDR-
BT applications separated by a week, each composed of two
fractions of 7 Gy nominal delivered in two consecutive days.
In each HDR-BT fraction, the volumes of interest receive the
doses shown in Table 1, figures which are converted into EQD2
considering ˛/ˇ = 10 Gy for the tumor and ˛/ˇ = 3 Gy for the ORs.
The total dose delivered by EBRT is also transformed to EQD2
and the result, shown in the last column of Table 1, corre-
sponds to the summation in EQD2 of the 4 HDR-BT fractions
and the total dose delivered by EBRT. In this example, only
the most common ORs, the bladder, rectum and sigmoid, are
included.
4. Overall treatment time effect
The cellular proliferation of many tumors has an important
influence on the result of radiotherapy,46 and it also explains
the reason why a prolongation of the total treatment time
produces a tumor control probability reduction for patients
treated exclusively with radiotherapy, or with surgery and
chemotherapy followed by radiotherapy.47–49 This is so in the
case of the cervix,9,13,50–55 even employing chemotherapy,56
which is why it is considered to be category 1 according to
The Royal College of Radiologist recommendations.57 That is
to say, they are patients with a cancer type for which it is evi-
dent that the prolongation of treatment does affect the results,
having been treated with curative intention, particularly in
the case of combined treatments. Therefore, patients receiv-
ing EBRT plus BT should not have the overall time of their
treatments prolonged.
In order to include the effect of the proliferation in the LQ
isoeffect equation, a term can be added accounting for the
increment of the cell number as time passes. If for that pur-
pose, as usual, the exponential growth model is utilized, the
LQ survival equation may be written as58:
− ln S = nd(˛ + ˇd) − ln 2
Teff
T (10)
where T is the total time to deliver the treatment and Teff the
total effective doubling time. Thus, we obtain:






with  = ln 2/(˛Teff).  is known as the time factor and, although
it has units of absorbed dose per time, it does not represent the
dose needed to compensate for the repopulation effect caused
by the addition of treatment days, but the BED required for
that compensation. Considering values for the parameter ˛
between 0.2 and 0.4 Gy−1 and values for Teff between 3 and 6
days,54  takes an average value of 0.5 Gy/day, and for highly
proliferative and radio resistant tumors  may be bigger than
1 Gy/day.
Some tumors have shown a phenomenon known as accel-
erated repopulation, which is an increase in the proliferation
rate in respect to that of the tumor before the beginning of the
therapy, as the treatment progresses.46,59 Since the acceler-
ated repopulation manifests several weeks after the treatment
is initiated, Eq. (11) can be modified to consider this fact:





−  max(T − T0, 0) (12)
That is to say, the total time effect does not occur before
a time T0 from the beginning of the treatment, because
max(T − T0, 0) produces a value other than 0 only if T is greater
than T0. For the cervix tumor, the estimation for T0 is 19 days
(CI95%).54
With the change in the LQ model expressed in Eq. (11), we
should take into account the total treatment time in the EQD2
assessment. Given a treatment schedule (D, d, T), we can define
a biologically effective dose delivered with a schedule of 2 Gy
per fraction in a total time T′ as follows:
BED(EQD2T′ , 2, T′) = BED(D, d, T) (13)










− (T − T′)
]
(14)
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Fig. 1 – Representation of 7 different examples of radiotherapy schedules combining EBRT with HDR-BT. The red bars
represent the days of EBRT; the long gray bars represent the weekends, in which there is not treatment; the short gray bars
represent days in which there is not EBRT treatment, since it already finished; the black bars represent the days of HDR-BT;
the blue line represent the recommended total treatment time limit of 8 weeks. The total treatment time, in days, is also
displayed.
Table 2 – Values of EQD239days for the treatment schedules of Fig. 1.
BT beginning Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
Overall treatment time (days) 39 39 40 47 54 61 68
EQD239days
(Gy)
 = 0.5 Gy/day 83.9 83.9 83.5 80.6 77.7 74.8 71.8
 = 1.5 Gy/day 83.9 83.9 83.1 77.3 71.4 65.6 59.8
















− (T − T′)
]
(15)
where DEBRT and dEBRT are, respectively, the total dose and the
dose per fraction delivered in EBRT, DBT and dBT the total dose
and dose per fraction delivered in HDR-BT, T the total time of
the combined treatment and T′ the total time of the reference
schedule delivered at 2 Gy per fraction.
In order to examine the total time effect in the result over
the tumor of the combined treatment of EBRT and HDR-BT,
we will contemplate a common clinical situation: a combined
schedule consisting of 45 Gy of EBRT, delivered in fractions of
1.8 Gy, plus 4 fractions of 7 Gy of HDR-BT delivered in 2 appli-
cations or implants with 2 fractions each, given on Thursday
and Friday of 2 consecutive weeks.
We assume that no interruptions happen and that the
treatment starts on Monday, but the choice of the 2 weeks
in which the HDR-BT is delivered is different between institu-
tions. We are going to study the cases in which the HDR-BT
starts, in the earliest case, the third week and it is separated
from the beginning of the treatment by one week at a time;
that is, the total time will amount to 39 days for the HDR-BT
in weeks 3 and 4 or weeks 4 and 5, and will be increased when
HDR-BT starts from week 5 on, amounting to 68 days in the
longest schedule (Fig. 1). Now it is not necessary to perform
a correction like that suggested in Eq. (12), as in this case the
total treatment time is always longer than 19 days.
For the computation of EQD2, we take a reference time
T′ = 39 days, that is, we calculate EQD239days. We assume
˛/ˇ = 10 Gy and two values for , 0.5 and 1.0 Gy/day, which
reflect situations of moderate and high proliferation, respec-
tively. The results are shown in Table 2, where remember that
the recommendations establish a time limit of 8 weeks for the
whole treatment.9,12–14
Although the EQD239days values indicate a reduction of the
effectiveness of the treatment when the overall treatment
time increases, it is better to estimate this reduction by means
of the tumor control probability (TCP) associated to each treat-
ment scheme. To do so, following the previous example, we









where D50 is the total dose needed to reach 50% of control and
 is the gradient of the dose–response relation normalized in
D50.
In order to perform the calculations, we need the values
of the parameters in Eq. (16). We use the data of the work
of Huang et al.54 which can be seen in Table 3. Table 3 also
includes the computation of the EQD239days, which allows fit-
ting the free parameters in Eq. (16) to those data to obtain
D50 = EQD239days,50 and  (Fig. 2). The fit has been performed
with Mathematica version 10 (Wolfram Research, Inc.). The
experimental data and the fit results are shown in Fig. 2. We
obtain results for the TCP which are in accordance with the
literature.9
Once these fits have been performed, we can obtain the
drop of tumor control associated with the increase of the com-
bined treatment duration. The results are shown in Fig. 3.
The lack of linearity of the TCP dependence on the overall
treatment time increment implies that the TCP drop grows
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Table 3 – Data of Huang et al.54 for the total dose of a schedule of 1.8 Gy per fraction and control probability for 11 groups
of patients with different overall treatment times. In the columns 3 and 4, the values of EQD239days are shown for  = 0.5
and 1.0 Gy/day, respectively.
EQD1.8 (Gy) Overall treatment time (days) EQD239days (Gy) TCP
 = 0.5 Gy/day  = 1.0 Gy/day
61 54 53.7 47.5 0.33
63 65 51.1 40.3 0.50
81 38 80.1 80.5 1.00
82 46 77.7 74.8 0.67
80 55 72.0 65.3 0.81
81 64 69.2 58.8 0.75
80 76 63.3 47.8 0.67
90 41 87.7 86.8 1.00
87 56 78.5 71.4 0.86
88 70 73.6 60.7 0.80
99 67 85.9 74.0 0.80
Fig. 2 – Probability control data from the work of Huang
et al.54 transformed to obtain the EQD239days equivalence
and fits of the control probability model (16) to those data.
Red squares correspond to  = 1.0 Gy/day and black circles to
 = 0.5 Gy/day. The results of the fit of (16) to the data in
Table 3 are also shown. The confidence interval is referred
to as 95%.
bigger as the time delay increases (Fig. 3a). Therefore, the TCP
reduction becomes more and more important as the over-
all treatment time raises (Fig. 3b). Consequently, each week
of increase in the total treatment time produces a gradually
worsening effect.
Finally, the total dose (and dose per fraction) of HDR-BT
can be computed in order to compensate the tumor control
loss produced by the increase in the total treatment time with
respect to the one which is 39 days long. This is shown in
Table 4, in which it can again be seen that the later the HDR-
BT initiates, the bigger the dose per fraction correction will
need to be. Such correction points in the same direction as
the results obtained by Tanderup et al.9 According to our cal-
culations, an increase in EQD2 of 5.83  Gy per week is needed
to compensate the TCP loss. Tanderup et al.9 indicate that
5 Gy are required to compensate an increase of the overall
treatment time of 1 week, a result which is within the inter-
val considered here for  = 0.5 and  = 1, with a tumor control
loss between 1% and 2.5% depending on the tumor size. Other
authors report a TCP loss between 0.67% and 1.6% per day of
increase of the total treatment time above 55 days.53,55,56
Fig. 3 – (a) Tumor control as a function of the increase in the
total combined treatment time above 39 days. (b) Absolute
loss of tumor control with respect to the treatment with
duration of 39 days. The results for  = 1.0 Gy/day are
represented by the discontinuous red line and for
 = 0.5 Gy/day, by the continuous black line.
In light of the above, if an absorbed dose of 85–90 Gy EQD2
is recommended for this combined treatment, such a recom-
mendation should also consider the overall treatment time.
In addition, it is important to take into account that the
EBRT may be prolonged due to treatment interruptions and,
therefore, it is essential to manage them adequately.
However, the TCP drop with the overall treatment time may
reflect a bad prognosis of the treatment, the relation with cel-
lular proliferation being unclear, that is, patients with bad
prognosis would have longer overall treatment times.61 Some
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Table 4 – Values of dose per fraction and total dose to compensate the tumor control loss, with respect to that achieved
with the scheme of 39 days, when the total treatment time increases.
Beginning of HDR-BT Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
Overall treatment time (days) 39 39 40 47 54 61 68
dBT
(Gy)
 = 0.5 Gy/day 7 7 7.1 7.4 7.8 8.1 8.4
 = 1.5 Gy/day 7 7 7.1 7.8 8.5 9.1 9.7
institutions’ experiences indicate that the prolongations of the
total treatment time are a result of poor coordination between
EBRT and BT.55
5. Uncertainties and variability
As Eq. (15) indicates, EQD2 depends on the value considered
for ˛/ˇ. As we have seen, in order to perform the calcula-
tions for the combined treatment, generic values of ˛/ˇ =3 Gy
and ˛/ˇ = 10 Gy are recommended for late-responding normal
tissue and tumor response, respectively.1 Nevertheless, there
are several reasons why the generic values taken for ˛/ˇ may
change or be different than the ones employed as the refer-
ence. We will address such reasons further on.
These generic values are affected, in the first place, by an
important uncertainty in their clinical determination. Besides,
their average values may change due to the progress in the
state of the art. In fact, this has already happened for the ˛/ˇ
value considered for prostate cancer in recent years62 and also
for an important tissue in our case, the bladder, for which an
˛/ˇ value as low as 0.4 Gy is suggested,63 which would imply a
much bigger sensitivity of this organ for high doses per frac-
tion than that currently supposed. Another important aspect
that should be taken into account is the variability in the
response between patients, which makes the use of a generic
value for ˛/ˇ more uncertain.
Considering any of the reasons why the ˛/ˇ value has such
an important uncertainty, one can analyze the influence of
this uncertainty in the estimation of EQD2 by means of a
simple Monte Carlo simulation, performed in Mathematica
version 10 (Wolfram Research, Inc.), in a certain case in which
Eq. (15) is utilized. This can now be applied to the example in
Section 3.1.
For the HDR-BT with 4 fractions, the following is assumed:
for the D90 of the CTVHR a mean value of dose per fraction
of 7.2 Gy, for the D2cc of the bladder, a mean value of 5.7 Gy
per fraction and for the D2cc of the rectum and sigmoid (we
would not distinguish between them since they both receive
very similar doses and have the same tolerance) a mean value
of 4.2 Gy per fraction, as we can see in Table 1; it is assumed
that the dose distribution produced by EBRT is homogeneous
for the tumor and ORs. Now it is supposed that ˛/ˇ may change
according to a normal distribution N[˛/ˇ,], where ˛/ˇ is the
average reference value for each tissue (10 Gy for the tumor
tissue and 3 Gy for the normal one) and  is the standard
deviation, which is taken as 30%, a value which has been
chosen from the typical uncertainties in the clinical studies
that provide estimations of ˛/ˇ (the reader may take a look
at the values for rectal toxicity64 or skin fibrosis, intestine
late effects and skin and breast cancers as examples in Table
9.1 of Joiner and van der Kogel65) and that, therefore, maybe
under-estimates the total uncertainty. It will be considered the
Fig. 4 – (a) EQD2 distributions for the D90 of the CTVHR
(black squares), EQD2bladder and EQD2rectum for D2cc of the
bladder (white circles) and the rectum (white squares). (b)
Contribution of each treatment phase to the final EQD2 for
the bladder. Uncertainties correspond to a confidence
interval of 95%.
reference schedule of 39 days long in the previous section.
With these assumptions, we will perform a simulation with
a high number of events (25,000 of them, so that we have good
statistics), which will provide values for the D90 of the CTVHR,
EQD2tumor, and for the D2cc of the normal tissues, EQD2bladder
and EQD2rectum. The contribution of each phase of the total
treatment (EBRT plus HDR-BT) to the final EQD2 is also ana-
lyzed in the case of the bladder. The obtained distributions are
shown in Fig. 4.
As can be observed in Fig. 4a, the effect of the variabil-
ity, or the uncertainty, in ˛/ˇ, in the total EQD2 is relatively
small, since, having introduced a standard deviation of 30% in
this parameter, the standard deviation obtained for the EQD2
values is 3% for the tumor and the bladder, and 1.4% for the
rectum. Therefore, although it is important to consider the
uncertainty in our knowledge of ˛/ˇ, we could conclude that
the use of generic values for the tumor and the normal tis-
sues does not have a great influence on the EQD2 calculation,
unless the variation of ˛/ˇ is very important.
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Nevertheless, it is necessary to consider that the effect of
the change of ˛/ˇ is almost entirely due to the HDR-BT treat-
ment, as can be observed in Fig. 4b, where the distributions
corresponding to the EQD2 produced by EBRT and HDR-BT
have been separated. The variability in the case of EBRT is
very small, 0.7%, compared to that obtained for HDR-BT, 7%;
and since the dose per fraction of EBRT is less than 2 Gy, the
tail of the distribution has the opposite direction as the tail
of the distribution of the HDR-BT treatment, which produced,
because of its influence, the whole tail of the distribution of
EQD2. Note that in the case of HDR-BT, an increase in the ˛/ˇ
respect to the one taken as reference (which makes EQD2 drop,
left side of the distributions) has a smaller effect in EQD2 than
a decrease of the same quantity (which makes EQD2 increase,
right side of the distributions), since the absolute value of the
derivative of EQD2 with respect to ˛/ˇ raises more quickly
when ˛/ˇ decreases. For EBRT delivered with doses per fraction
smaller than 2 Gy, since the sign of the derivative is positive,
the tail of the distribution goes in the opposite direction; now
an increase of ˛/ˇ respect to that taken as reference makes
EQD2 increase. In this sense, it can be seen that a drop of the
dose per fraction received by the normal tissue in the HDR-BT
produces a smaller uncertainty in the determination of EQD2,
as can be observed in the histogram of the rectum compared
to that of the bladder in Fig. 4a. Finally, note that the consid-
ered uncertainty span a range which exceeds the tolerance
value of the bladder (90 Gy), while it does not for the rectum
(75 Gy), although this applies for this example presented here
in particular. Therefore, and as a conclusion, it is convenient to
perform an estimation of the uncertainty associated with the
computation of EQD2 and consider, if appropriate, the pos-
sibility of exceeding the tolerance doses or not reaching the
established values for the CTVHR doses.
Secondly, a way of taking into account the whole biologi-
cal effect due to the heterogeneity of the dose distribution, so
important in BT, and to the dependence with the irradiated
volume of the different organs, characterized by a parame-
ter that is usually denoted as n (which varies between 0, for
series tissues such as the spinal cord, and 1, for parallel tis-
sues such as the lung), is to use an effective value for ˛/ˇ,
˛/ˇeff, which allows the employment of the basic equations
of the LQ model66,67 just by replacing the parameter ˛/ˇ by
˛/ˇeff. Therefore, the effect of the heterogeneity and the type
of tissue, regarding the parameter of volume, can be consid-
ered by means of a variation in ˛/ˇ; that is, certain irradiation
circumstances of a particular tissue conditions the ˛/ˇ value.
Consequently, it is possible to distinguish between the ˛/ˇ
values corresponding to the EBRT, and the ˛/ˇ values corre-
sponding to the HDR-BT. In general this distinction will affect
normal tissue more, which is usually irradiated with impor-
tant heterogeneities (even in EBRT when techniques such as
IMRT or VMAT are used), than tumor tissue, which irradiation
is more homogeneous.
Additionally, the validity of the LQ model has been ques-
tioned when the doses per fraction are high, and the doses
employed in HDR-BT for the combined treatments in this work
(7 Gy per fraction in the given example) are considered to be
in the limit of high doses. This is a controversial issue which,
it can be said, has not been solved yet,67 but it admits a prag-
matic approximation which allows a description of the clinical
Fig. 5 – Ratio between EQD2 computed with Eq. (17) and
EQD2 computed with Eq. (15) considering fixed values for
(˛/ˇ)E equal to 3 Gy and 10 Gy for the normal tissue and the
tumor, respectively, as a function of the difference between
(˛/ˇ)E and (˛/ˇ)B. We have considered an EBRT schedule of
45 Gy in fractions of 1.8 Gy plus 4 fractions of 7 Gy of
HDR-BT.
results despite our lack of awareness of the biological mecha-
nisms which produce them. Therefore, it would be sufficient
to consider that the survival model LQ is just an empirical
approximation which is valid in a limited range of doses. In
this way, we could take an adequate fit of the LQ model in
the low or intermediate dose region, with a value (˛/ˇ)L, and
another one in the intermediate to high doses region, with a
value (˛/ˇ)H, so that the predictive capacity of the LQ model
holds in each region.
Under this pragmatic perspective, and taking into account
the considerations of the two previous paragraphs, the equa-
tion for EQD2, without considering the time, could be written
















where the values of (˛/ˇ)E and (˛/ˇ)B represent the adequate
values for the conditions of the dose distributions in the cases
of the EBRT and the HDR-BT, respectively.
Fig. 5 shows the ratio between the EQD2 computed accord-
ing to Eq. (17) and the EQD2 computed according to Eq. (15)
with  = 0, considering fixed values for (˛/ˇ)E equal to 3 Gy and
10 Gy for the normal tissue and the tumor, respectively, as a
function of the difference between (˛/ˇ)E and (˛/ˇ)B. As can
be seen, considering two different values of ˛/ˇ for EBRT and
HDR-BT has an effect which is more important for low values
of ˛/ˇ, which correspond to normal tissues, than in the case
of tumors, with higher ˛/ˇ.
It is usual to consider that the LQ model over-estimates
the cellular death in the range of dose per fraction under con-
sideration for HDR-BT,68 therefore, if we do not consider the
effect of the heterogeneity, (˛/ˇ)B is bigger than (˛/ˇ)E and the
EQD2 computed with the usual Eq. (15) will be bigger than that
produced by Eq. (17).
In addition to the uncertainty associated to the value of
 and its variability between patients, the overall treatment
time effect on the effectiveness of the radiotherapy on cervix
cancer, which is only considered in the case of the tumor, it is
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affected also by the ˛/ˇ value, since the equivalent dose lost
per day of increase in the total treatment time is written as:
EQD2T′ =
˛/ˇ
2 + ˛/ˇ (T − T
′) (18)
As done previously, an assessment can be made of the
effect of the variability in ˛/ˇ and , although it is now much
simpler. Since ˛/ˇ is in the numerator and in the denominator
of the quotient, its influence is very small, hence, the uncer-
tainty in  translates directly to EQD2, since the dependence
is linear.
All these considerations should serve as a general warn-
ing about the use of generic values of ˛/ˇ. The uncertainty in
˛/ˇ is important to determine the dose–response relationships
of the different tissues, tumor and normal, and to estimate
the final result of the treatment. According to the issues ana-
lyzed in this section, the values utilized in the computations
may change with respect to the current consensual values
and, therefore, it is fundamental to adequately register all the
variable dosimetric aspects of the treatments without radio-
biological correction, and so its results.1
6. Conclusions
A radiobiological description of the currently recommended
method of summation of the external beam radiotherapy and
brachytherapy phases for the treatment of cervix cancer is
performed. Some important points regarding the use of the
radiobiological LQ model in the assessment of the comprehen-
sive dosimetry of the whole treatment have been addressed.
A prolongation of the overall treatment time above the rec-
ommended 8 weeks worsens the tumor control probability
considerably. Therefore, it is important to carefully manage
the temporal features of the delivery of the treatment, such
as interruptions to the treatment and when to begin the BT
phase.
It can be concluded that estimation of the EQD2 is not dra-
matically affected by the uncertainty of the most important
parameters of the LQ model, which consolidates the LQ model
as a solid tool for the assessment of the relevant dosimetric
quantities.
The validity of the LQ model when the dose per fraction
is higher than 6–10 Gy is a controversial issue that may be
pragmatically solved in view of the analysis performed in
this work, which supports the unexplored idea of considering
two different ˛/ˇ values, one for each of the typical regions
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